{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:53:27Z","timestamp":1791377607097,"version":"4.3.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Endocrine therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a significant clinical problem. A potential mechanism of resistance involves changes in gene expression secondary to epigenetic modifications, which might be reversed with the use of histone deacetylase (HDAC) inhibitors such as entinostat. The ENCORE 301 phase II randomized, placebo-controlled study demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS), with the addition of entinostat to exemestane in patients with HR-positive advanced breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI). These results prompted the development of E2112, a phase III registration trial which is investigating entinostat\/placebo in combination with exemestane in patients with locally advanced or metastatic breast cancer who have experienced disease progression after a non-steroidal AI. E2112 aims to validate the preclinical and clinical findings supporting the role of HDAC inhibitors in overcoming resistance to endocrine therapy in breast cancer, and ultimately improve outcomes for patients with advanced breast cancer.<\/jats:p>","DOI":"10.1038\/s41523-017-0053-3","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T14:01:09Z","timestamp":1515160869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["E2112: randomized phase iii trial of endocrine therapy plus entinostat\/placebo in patients with hormone receptor-positive advanced breast cancer"],"prefix":"10.1038","volume":"4","author":[{"given":"Sri Lakshmi Hyndavi","family":"Yeruva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amye J.","family":"Tevaarwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-2010","authenticated-orcid":false,"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"53_CR1","first-page":"571","volume":"27","author":"RM Connolly","year":"2013","unstructured":"Connolly, R. M. & Stearns, V. Postmenopausal hormone receptor-positive advanced breast cancer. Oncology 27, 571\u2013572 (2013).","journal-title":"Oncology"},{"key":"53_CR2","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/S0140-6736(16)32419-9","volume":"389","author":"NC Turner","year":"2017","unstructured":"Turner, N. C., Neven, P., Loibl, S. & Andre, F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet 389, 2403\u20132414 (2017).","journal-title":"Lancet"},{"key":"53_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520\u2013529 (2012).","journal-title":"N. Engl. J. Med."},{"key":"53_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"53_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"53_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10911-012-9263-3","volume":"17","author":"R Connolly","year":"2012","unstructured":"Connolly, R. & Stearns, V. Epigenetics as a therapeutic target in breast cancer. J. Mammary Gland. Biol. Neoplasia. 17, 191\u2013204 (2012).","journal-title":"J. Mammary Gland. Biol. Neoplasia."},{"key":"53_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1517\/13543784.2011.613822","volume":"20","author":"J Knipstein","year":"2011","unstructured":"Knipstein, J. & Gore, L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert. Opin. Investig. Drugs 20, 1455\u20131467 (2011).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"53_CR8","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","volume":"117","author":"D Buglio","year":"2011","unstructured":"Buglio, D. et al. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 117, 2910\u20132917 (2011).","journal-title":"Blood"},{"key":"53_CR9","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu, W. S., Parmigiani, R. B. & Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26, 5541\u20135552 (2007).","journal-title":"Oncogene"},{"key":"53_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1175371","volume":"325","author":"C Choudhary","year":"2009","unstructured":"Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834\u2013840 (2009).","journal-title":"Science"},{"key":"53_CR11","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1535-7163.MCT-10-0582","volume":"9","author":"RK Srivastava","year":"2010","unstructured":"Srivastava, R. K., Kurzrock, R. & Shankar, S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol. Cancer Ther. 9, 3254\u20133266 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"53_CR12","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. et al. Randomized phase ii, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128\u20132135 (2013).","journal-title":"J. Clin. Oncol."},{"key":"53_CR13","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1535-7163.MCT-13-0345","volume":"12","author":"GJ Sabnis","year":"2013","unstructured":"Sabnis, G. J., Goloubeva, O. G., Kazi, A. A., Shah, P. & Brodie, A. H. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol. Cancer Ther. 12, 2804\u20132816 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"53_CR14","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1158\/1535-7163.MCT-14-0778","volume":"14","author":"A Schech","year":"2015","unstructured":"Schech, A., Kazi, A., Yu, S., Shah, P. & Sabnis, G. Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells. Mol. Cancer Ther. 14, 1848\u20131857 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"53_CR15","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. USA 111, 11774\u201311779 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"53_CR16","doi-asserted-by":"publisher","first-page":"e30815","DOI":"10.1371\/journal.pone.0030815","volume":"7","author":"L Shen","year":"2012","unstructured":"Shen, L. et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS. One 7, e30815 (2012).","journal-title":"PLoS. One"},{"key":"53_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"53_CR18","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1200\/JOP.2016.012161","volume":"12","author":"KA Kern","year":"2016","unstructured":"Kern, K. A. Trial design and efficacy thresholds for granting breakthrough therapy designation in oncology. J. Oncol. Pract. 12, e810\u2013e817 (2016).","journal-title":"J. Oncol. Pract."},{"key":"53_CR19","doi-asserted-by":"publisher","first-page":"e1219008","DOI":"10.1080\/2162402X.2016.1219008","volume":"5","author":"Y Tomita","year":"2016","unstructured":"Tomita, Y. et al. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. Oncoimmunology 5, e1219008 (2016).","journal-title":"Oncoimmunology"},{"key":"53_CR20","doi-asserted-by":"crossref","unstructured":"Kornblum, N. et al. PrECOG 0102: a randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy. SABCS 2016 (Abstract S1-02) (2017).","DOI":"10.1158\/1538-7445.SABCS16-S1-02"},{"key":"53_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn, R. S. et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25\u201335 (2015).","journal-title":"Lancet Oncol."},{"key":"53_CR22","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 375, 1738\u20131748 (2016).","journal-title":"N. Engl. J. Med."},{"key":"53_CR23","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr.","year":"2017","unstructured":"Sledge, G. W. Jr. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR\u2009+\u2009\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875\u20132884 (2017).","journal-title":"J. Clin. Oncol."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-017-0053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-017-0053-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-017-0053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T22:12:50Z","timestamp":1671574370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-017-0053-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["53"],"URL":"https:\/\/doi.org\/10.1038\/s41523-017-0053-3","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]},"assertion":[{"value":"4 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.C. has received research grants for clinical trials (paid to institution) from Novartis, Puma Biotechnology, Genentech, Merrimack Pharmaceuticals, Clovis, Merck. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}